The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I think frumkin didnt get the job or keep it. through ability. He was used initially by tne founder (a good friend of his), to manage reg fall out, and since it looks like hes been used by gilinski to do his capital injection, for discounted shares move.
Some one talking sense. Shorters arent necessarily passive, and can pro actively force the share price down with information and disinformation. They could easlly be the tool of a major shareholder/financial interest looking to destablise the company, so they can come to the reacue with a an exclusive capital raise etc, in exchange for discounted shares, which means a dilution.
Tosh. Mortgage arrears lower than expected/ allowed for across the board.
Selling the mortgage book would have severely reduced profit, unless proceeds can be used to achieve a higher return.
Board and majority ahareholder need to focus on restoring metro credibility to markets and investors.
Yes, it would. Its the shorters that outed the capital funding issue, and amplified it to the extent they were forced to deal with it prematurely, ie immediately, rather than in an organised fashion in due course.
The current situation was engineered by the shorters, and did they have help?
Once the dilution/capital raise has been completed, metro will be on more solid ground. The issue going forwards is that the profit metro can make is severely limited by its capital funding. They cant make profits like they have in the past, when they werent following regs.
The major shareholder and ceo are putting in signigicant sums. This must be based on sound due diligence, and expect to benefit going forwards. More so the ceos £2 million. Thats more telling than the major share holder, who is protecting theiŕ existing share holding.
Given that shorters havent reduced their positions, can only assume major shareholder is behind them, as they dont lose anything, if share price increases. Seems too risky for shorters in they are unrelated to major shareholder to remain, as going forwards if deal is completed, they will have limited effect on metro?
Cant understand the recovery in price. Mab share price will recover well in future, but currently, outlook not good. New biz fell off a cliff in september. Likely to contine for at least rest of this year, resulting in 2024 h2 results suffering, due to the time lag for mortgage process to complete and pay. Relying on product transfers is not ideal, as most lenders only pay 50% of normal commission paid. Also, harder for advisers justify charging the client a fee for a pt, when the client can contact the lender themselves to do it. Life protection sales drive mab"s revenue, and are much stronger on purchases, which arent happening currently. A return to a stronger house buying market is essential to them.
Agree. They played their hand well. Maxmised uncertainty, and some came in relelatively late and low.
Execs getting rewarded with discounted shares seems well out of order. Rewarded for having their pants pulled down.
Saving grace for metro have been tangible assets created by legacy issues/practices. Realising some with a second tranche of their mortgage book to be sold, suggests their model doesnt work, ie profit made in past while operating outside of regulation, is propping them up. Can only last so long.